Safety and Efficacy of Recombinant Activated Factor VII (Novoseven) Administration in Pediatric ECMO Patients

被引：1
|
作者：
Kasniya, G. [1 ]
Salisbury, C. [2 ]
Heard, M. L. [2 ]
Maher, K. [3 ]
Deshpande, S. R. [3 ]
机构：
[1] Childrens Healthcare Atlanta, Pediat Cardiol, Atlanta, GA USA
[2] Childrens Healthcare Atlanta, Atlanta, GA USA
[3] Emory Univ, Childrens Healthcare Atlanta, Pediat Cardiol, Atlanta, GA 30322 USA
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2016年 / 35卷 / 04期
关键词：
D O I：
10.1016/j.healun.2016.01.1217
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1183
引用
收藏
页码：S421 / S422
页数：2
相关论文
共 50 条
  • [1] RECOMBINANT ACTIVATED FACTOR VII FOR REFRACTORY BLEEDING IN PEDIATRIC PATIENTS ON ECMO
    Orr, Hillary
    Damhoff, Heather
    Zoeller, Cindy
    Mayes, Shannon
    CRITICAL CARE MEDICINE, 2016, 44 (12)
  • [2] The comparison of efficacy between recombinant activated factor VII (ARYOSEVEN®) and NOVOSEVEN® in patients with congenital factor VII deficiency
    Faranoush, M.
    Hassan, A.
    Toogeh, G.
    Karimi, M.
    Eshghi, P.
    Managchi, M. R.
    Hamid, H.
    Kamyar, K.
    Heshmat, R.
    Keykhahi, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 1198 - 1199
  • [3] A COMPARISON OF EFFICACY BETWEEN RECOMBINANT ACTIVATED FACTOR VII (ARYOSEVEN™) AND NOVOSEVEN® IN PATIENTS WITH CONGENTIAL FACTOR VII DEFICIENCY
    Abolghasemi, Hasan
    Khoein, Babak
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (06) : E59 - E59
  • [4] Efficacy of recombinant activated factor VII (rFVIIa; NovoSeven®) in obstetrical haemorrhagic shock
    S Sobieszczyk
    GH Breborowicz
    B Kubiaczyk
    T Opala
    Critical Care, 7 (Suppl 2):
  • [5] Comparison of efficacy and safety between aryogen recombinant activated factor VII (Aryoseven™) and Novoseven® in the main on-label (approved) indications of recombinant activated factor VII in Iran
    Eshghi, P.
    Kamyar, K.
    Abolghasemi, H.
    Karimi, M.
    Faranoush, M.
    Toogeh, G.
    Hoorfar, H.
    Dehdezi, B. K.
    Khoeiny, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 : 30 - 30
  • [6] Efficacy of recombinant activated factor VII (NovoSeven) in two patients affected by acquired hemophilia with retroperitoneal hematoma
    Ciavarella, N
    Schiavoni, M
    Ettorre, C
    Gilibertri, MG
    Mascolo, E
    Stefanile, C
    Valenzano, E
    THROMBOSIS AND HAEMOSTASIS, 1997, : PS346 - PS346
  • [7] Efficacy and safety of activated recombinant factor VII in cardiac surgical patients
    Hardy, Jean-Francois
    Belisle, Sylvain
    Van der Linden, Philippe
    CURRENT OPINION IN ANESTHESIOLOGY, 2009, 22 (01) : 95 - 99
  • [8] A Comparison Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Congenital Factor VII Deficiency
    Faranoush, M.
    Abolghasemi, Hassan
    Toogeh, Gh.
    Karimi, M.
    Eshghi, P.
    Managhchi, M.
    Hoorfar, H.
    Dehdezi, B. Keikhaei
    Mehrvar, A.
    Khoeiny, B.
    Kamyar, K.
    Heshmat, R.
    Baghaeipour, M. R.
    Mirbehbahani, N. B.
    Fayazfar, R.
    Ahmadinejad, M.
    Naderi, M.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2015, 21 (08) : 724 - 728
  • [9] RECOMBINANT ACTIVATED FACTOR-VII - SAFETY AND EFFICACY
    GLAZER, S
    TRANSFUSION, 1994, 34 (08) : 728 - 728
  • [10] Use of activated recombinant factor VII (NovoSeven) - During neurosurgery
    Karadimov, D
    Binev, K
    Nachkov, Y
    Platikanov, V
    JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY, 2003, 15 (04) : 330 - 332
12345